Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated by Analysts at Raymond James Financial

Raymond James Financial began coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage issued a strong-buy rating on the stock.

Several other research analysts have also commented on the company. BTIG Research boosted their price target on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Guggenheim lifted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $38.57.

Maze Therapeutics Trading Up 2.2%

Shares of Maze Therapeutics stock traded up $0.69 during trading on Thursday, hitting $32.53. 912,658 shares of the stock traded hands, compared to its average volume of 338,058. The stock’s fifty day simple moving average is $27.53 and its 200 day simple moving average is $18.01. The firm has a market cap of $1.57 billion and a P/E ratio of -1.56. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $34.29.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth about $226,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maze Therapeutics during the first quarter worth $145,000. Nuveen LLC acquired a new stake in shares of Maze Therapeutics in the first quarter valued at about $125,000. Bank of New York Mellon Corp purchased a new position in shares of Maze Therapeutics in the first quarter worth about $190,000. Finally, Octagon Capital Advisors LP acquired a new position in Maze Therapeutics during the first quarter worth about $5,153,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.